文献速递冠心病血脂与心血管预防

极高危ASCVD患者中等强度他汀联合依折麦布对比高强度他汀单药治疗:RACING随机临床试验事后分析

Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该研究为RACING试验事后分析,纳入3780例ASCVD患者,其中1511例(40.0%)为极高危。在极高危及非极高危患者中,中等强度他汀联合依折麦布与高强度他汀单药相比,3年主要终点事件无显著差异,但联合治疗组LDL-C水平更低且耐受性更好。

要点

  • 极高危ASCVD患者中,联合治疗与高强度他汀单药的主要终点风险相似(HR 0.96)。
  • 联合治疗组LDL-C中位数及达标率(<70 mg/dL)均显著优于高强度他汀单药组。
  • 联合治疗组因不耐受停药或减量的比例显著低于单药组。

核心结论

  • 在极高危ASCVD患者中,中等强度他汀联合依折麦布与高强度他汀单药相比,3年主要心血管终点事件无显著差异。

研究设计与样本

  • RACING随机临床试验的事后分析,在韩国26个中心进行,纳入3780例确诊ASCVD患者,随机接受中等强度他汀联合依折麦布或高强度他汀单药治疗。

主要发现

  • 极高危患者占40.0%,其3年主要终点发生风险显著高于非极高危患者(HR 1.42;95% CI 1.15-1.75)。
  • 极高危患者中,联合治疗组与单药组主要终点发生率分别为11.2%和11.7%(HR 0.96;95% CI 0.71-1.30)。
  • 非极高危患者中,联合治疗组与单药组主要终点发生率分别为7.7%和8.7%(HR 0.88;95% CI 0.66-1.18)。
  • 极高危患者1年时LDL-C中位数联合治疗组为57 mg/dL,单药组为65 mg/dL(P < .001);非极高危患者分别为58 mg/dL和68 mg/dL。
  • 极高危患者1年时LDL-C<70 mg/dL的比例联合治疗组为73%,单药组为58%(P < .001);非极高危患者分别为72%和53%。

关键数值与推荐

  • 极高危定义依据2018年美国心脏协会/美国心脏病学会指南。
  • 主要终点为3年心血管死亡、冠脉或外周血运重建、心血管事件住院或非致命性卒中的复合终点。
  • 极高危患者中,联合治疗组因不耐受停药或减量的比例为4.6%,单药组为7.7%(P = .02)。
  • 非极高危患者中,联合治疗组因不耐受停药或减量的比例为5.0%,单药组为8.7%(P = .001)。

临床怎么用

  • 对于极高危ASCVD患者,中等强度他汀联合依折麦布可作为高强度他汀单药治疗的替代选择,尤其关注耐受性时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: High-intensity statin is strongly recommended in patients at very high risk (VHR) of atherosclerotic cardiovascular disease (ASCVD). However, concerns about statin-associated adverse effects result in underuse of this strategy in practice. OBJECTIVE: To evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in VHR and non-VHR patients with ASCVD. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Randomized Comparison of Efficacy and Safety of Lipid Lowering With Statin Monotherapy vs Statin/Ezetimibe Combination for High-Risk Cardiovascular Disease (RACING) open-label, multicenter, randomized clinical trial. The study was conducted from February 2017 to December 2018 at 26 centers in Korea. Study participants included patients with documented ASCVD. Data were analyzed from April to June 2022. INTERVENTIONS: Patients were randomly assigned to moderate-intensity statin with ezetimibe (rosuvastatin, 10 mg, with ezetimibe, 10 mg) or high-intensity statin monotherapy (rosuvastatin, 20 mg). Patients at VHR for ASCVD were defined according to the 2018 American Heart Association/American College of Cardiology guidelines. MAIN OUTCOMES AND MEASURES: The primary end point was the 3-year outcome of cardiovascular death, coronary or peripheral revascularization, hospitalization of cardiovascular events, or nonfatal stroke. RESULTS: A total of 3780 patients (mean [SD] age, 64 [10] years; 2826 male [75%]) in the RACING trial, 1511 (40.0%) were categorized as VHR, which was associated with a greater occurrence of the primary end point (hazard ratio [HR], 1.42; 95% CI, 1.15-1.75). There was no significant difference in the primary end point between those who received combination therapy and high-intensity statin monotherapy among patients with VHR disease (11.2% vs 11.7%; HR, 0.96; 95% CI, 0.71-1.30) and non-VHR disease (7.7% vs 8.7%; HR, 0.88; 95% CI, 0.66-1.18). The median low-density lipoprotein cholesterol (LDL-C) level was significantly lower in the combination therapy group than in the high-intensity statin group (VHR, 1 year: 57 [47-71] mg/dL vs 65 [53-78] mg/dL; non-VHR, 1 year: 58 mg/dL vs 68 mg/dL; P < .001). Furthermore, in both the VHR and non-VHR groups, combination therapy was associated with a significantly greater mean change in LDL-C level (VHR, 1 year: -19.1 mg/dL vs -10.1 mg/dL; 2 years: -22.3 mg/dL vs -13.0 mg/dL; 3 years: -18.8 mg/dL vs -9.7 mg/dL; non-VHR, 1 year: -23.7 mg/dL vs -12.5 mg/dL; 2 years: -25.2 mg/dL vs -15.1 mg/dL; 3 years: -23.5 mg/dL vs -12.6 mg/dL; all P < .001) and proportion of patients with LDL-C level less than 70 mg/dL (VHR, 1 year: 73% vs 58%; non-VHR, 1 year: 72% vs 53%; P < .001). Discontinuation or dose reduction of the lipid-lowering drug due to intolerance occurred less frequently in the combination therapy group (VHR, 4.6% vs 7.7%; P = .02; non-VHR, 5.0% vs 8.7%; P = .001). CONCLUSIONS AND RELEVANCE: Results suggest that the outcomes of ezetimibe combination observed in the RACING trial were consistent among patients at VHR of ASCVD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03044665.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee SJ, Cha JJ, Choi WG, et al. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37531130. doi:10.1001/jamacardio.2023.2222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。